SP16-3M

**SP16-3M** is a synthetic, highly selective peptide therapeutic derived from the carboxyl-terminus of alpha-1-antitrypsin (AAT, residues 364-380), modified for enhanced stability, bioavailability, efficacy, and LRP1 binding. It acts as a first-in-class LRP1 agonist, stimulating innate inflammation resolution by clearing harmful molecules and pathogens from cell surfaces, reducing inflammatory pathways, preventing cell death, and promoting repair via ERK/AKT signaling. Developed by Serpin Pharma, it shows no off-target effects, high potency (300x natural counterpart), and cost-effective production without plasma derivation; primarily indicated for chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer, with broader potential in inflammatory conditions like STEMI, COVID-19, HIV brain inflammation, and ischemia-reperfusion injury.[1][2][3][4][5][7][9]

Other names

SP16SP-16SP 16